Novo Nordisk stock falls as Medicare selects its marketed semaglutide medicines catering to T2D and obesity for price ...

Now that Novo Nordisk is the world’s weight-loss juggernaut, will it have to betray its first patients—type 1 diabetics?

Shares of Novo Nordisk NVO gained 2.8% on Wednesday likely because the analysts at UBS upgraded the company’s rating from ...

The European Commission has granted marketing authorisation for Novo Nordisk’s adult diabetes ... company’s latest prefilled insulin pen, FlexTouch, which has an easy auto-injector mechanism.

Health care, ride sharing, and the emerging world of YouTube entertainers are among industries leading investors have picked ...

Those in the jab trials, however, kept off between 10 and 25 per cent of their body weight over the same timeframe, depending ...

It has been estimated that 90% of medical device waste consists of single-use products or components, so a new initiative by Novo Nordisk to recycle pre-filled injection pens used by people living ...

According to the American Diabetes Association, approximately 8.4 million people in the United States need insulin to survive ...

In June, the Danish drugmaker Novo Nordisk said it would add 1.4 million square feet of production ... where it makes injectable finished products like insulin pens to treat diabetes.

Weight loss results Eli Lilly's obesity drug Zepbound — which saw a 300% increase in prescription fills throughout 2024 — led to higher weight loss than its competitor, Novo Nordisk's Wegovy.